Accelerating Development of Bioterrorism Vaccines
An Interview with Philip Russell
Vol. 06, No. 5, Oct.-Nov. 2002
Need to Understand Demand, Viewpoint, Vaccine Against Human Papilloma Virus, Malaria Vaccine Trials Underway in Africa, Bioterrorism Vaccines, Immunogenicity Assay Standardization, Ugandan Vaccine Summit, Industry Insider, Vaccine Briefs
Immunogenicity Assay Standardization Efforts Underway
By Emily Bass
This year saw the launch of three separate projects designed to ease comparison of results from vaccine trials by standardizing aspects of assays that measure cellular immune responses (Elispot and intracellular cytokine, or ICC) and neutralizing antibodies.
Industry Insider
Major Contracts Awarded for Anthrax, Malaria Vaccines
Malaria Vaccine Trials Underway in Africa
By Patricia Kahn
While AIDS researchers often say that HIV is one of the most formidable pathogens ever targeted for a vaccine, the same holds true for the parasites that cause malaria—a disease that claimed 1 to 2 million lives every year, 75% of them children under five.
Progress in the Search for a Vaccine Against Human Papilloma Virus
By Emily Bass
Merck presented two sets of encouraging data from Phase I and II studies of a vaccine against human papilloma virus (HPV) at the HPV Clinical Workshop and 20th International Papillomavirus Conference (4-9 October, 2002).
The Need to Understand Demand
Why Plans to Deliver AIDS Vaccines Are on Agendas Today
Ugandan Parliamentarians Gather for Vaccine Summit
By Emily Bass
On 12-13 August, 2002, a Policymakers Conference on HIV/AIDS and AIDS Vaccine Initiatives was held in Kampala, Uganda.
Vaccine Briefs
New Report On AIDS as Security Threat
Viewpoint
Settling into the New Groove: AIDS Vaccine Research 2002